目的 观察肾复康胶囊联合贝那普利治疗慢性肾小球肾炎的临床疗效。方法 选择2013年1月—2014年12月就诊于内蒙古医科大学附属医院的慢性肾小球肾炎患者78例,随机分为治疗组和对照组,每组各39例。对照组在常规治疗的基础上口服盐酸贝那普利片10 mg/次,1次/d;治疗组在对照组的基础上加服肾复康胶囊,5粒/次,3次/d。4周为1个疗程,两组患者均治疗3个疗程。比较两组的临床疗效,测定两组患者治疗前后24 h尿蛋白定量(24 h Pro)、尿红细胞计数(RBC)、尿β2-微球蛋白(β2-MG)以及肾功能指标尿素氮(BUN)、血肌酐(Scr)和血脂四项三酰甘油(TG)、胆固醇(TC)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)。结果 治疗后,治疗组、对照组的总有效率分别为94.87%、84.62%,两组总有效率比较差异有统计学意义(P < 0.05)。治疗后两组患者的24 hPro、RBC、β2-MG、BUN和Scr水平均较同组治疗前显著降低,同组治疗前后比较差异有统计学意义(P < 0.05、0.01),且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P < 0.05、0.01)。治疗后两组患者的TC、TG、LDL-C水平均较同组治疗前显著降低,但HDL-C水平明显升高,同组治疗前后比较差异有统计学意义(P < 0.05、0.01),且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P < 0.05)。两组患者治疗期间均未出现严重不良反应。结论 肾复康胶囊联合贝那普利片治疗慢性肾小球肾炎具有良好疗效,在减少尿蛋白定量、尿红细胞计数,降低血肌酐、血尿素氮方面要优于单用贝那普利片治疗,且未见严重不良反应,值得临床推广应用。

Objective To observe the clinical effect of Shenfukang Capsule combined with Benazepril Tablets in treatment of chronic glomerulonephritis. Methods Patients (78 cases) with chronic glomerulonephritis in the Affiliated Hospital of Inner Mongolia Medical University from January 2013 to December 2014 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were po administered with Benazepril Tablets at the basis of conventional therapy, 10 mg/time, once daily. And the patients in the treatment group were po administered with Shenfukang Capsule at the basis of control group, 5 capsules/time, three times daily. One course of treatment was 4 weeks. Two groups were treated for three courses. The clinical efficacy of two groups was compared. The other index were determined, such as the changes of 24 h urine protein (24 h Pro), urine red blood cell count (RBC), β2 microglobulin (β2-MG), renal function index serum creatinine (Scr), blood urea nitrogen (BUN), and four items of blood lipid tests, including three triacylglycerol (TG), cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL) of the patients. Results After treatment, the efficacies in the control and treatment groups were 94.87% and 84.62%, respectively, and there were differences between two groups (P < 0.05). After treatment, the levels of 24 h Pro, RBC, β2-MG, BUN, and Scr levels in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05, 0.01). And these indicators in treatment group improved better than those in the control group, with significant difference between two groups (P < 0.05, 0.01). After treatment, the levels of TC, TG, and LDL-C in two groups were significantly reduced, but the levels of HDL-C in two groups significantly increased, and the difference was statistically significant in the same group (P < 0.05, 0.01). And these indicators in treatment group improved better than those in the control group with significant difference between two groups (P < 0.05). After treatment, routine urine white blood cells and red blood cell count in two groups were significantly reduced, and index in the treatment group were obviously lower than those in the control group with significant difference between two groups (P < 0.05, 0.01). There were no adverse effects in both groups. Conclusion Shenfukang Capsule combined with Benazepril Tablets has a definite effect on reducing urine protein, RBC, Scr, and SUN than those in the treatment of Benazepril Tablets, without drug-related adverse reaction, which is worth clinical promotion.